Shopping Cart
Remove All
Your shopping cart is currently empty
BMS-986339 is an orally active, potent FXR agonist that engages His298 and ASN287 residues via H-bond formation. It is employed in research on primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH) due to its anti-fibrosis properties.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $2,270 | 10-14 weeks | 10-14 weeks | |
| 50 mg | $2,980 | 10-14 weeks | 10-14 weeks | |
| 100 mg | $4,000 | 10-14 weeks | 10-14 weeks |
| Description | BMS-986339 is an orally active, potent FXR agonist that engages His298 and ASN287 residues via H-bond formation. It is employed in research on primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH) due to its anti-fibrosis properties. |
| Targets&IC50 | CYP2C8:8 μM, CYP2C9:13.5 μM |
| Molecular Weight | 643.71 |
| Formula | C35H41F4N3O4 |
| Cas No. | 2477873-64-4 |
| Smiles | C(C)(C)(F)C1=NC(C23CCC(CN(C(=O)[C@H]4C[C@@](C(F)(F)F)(O)C4)C5=CC(=CC=C5)C6=CC=C(C(C)(C)O)C=C6)(CC2)CC3)=NO1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.